New pill shows promise against tough lung cancer in early trial
Disease control
Ongoing
This study tests a daily pill called lazertinib in 150 people with advanced non-small cell lung cancer that has specific EGFR mutations. The goal is to see how well the drug controls the cancer and delays its growth, while also checking for side effects. Participants have not had…
Phase: PHASE2 • Sponsor: Sehhoon Park • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC